A prospective, randomized trial of integrative medicine for women with ovarian cancer

Patricia L. Judson, Elizabeth L Dickson, Peter A Argenta, Yin Xiong, Melissa A Geller, Linda F Carson, Rahel G Ghebre, Amy L. Jonson, Levi S Downs

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: Despite increased use of integrative medicine in cancer therapy, little data exist on its efficacy. This prospective, randomized, pilot trial sought to evaluate the feasibility of combined modality integrative medicine (CM-IM) in women with ovarian cancer (OvCA) and evaluate its effects on quality of life (QoL), chemotherapy toxicity and immunologic profiles. Methods: Women with newly diagnosed OvCA requiring chemotherapy were offered enrollment. Those randomized to the experimental arm received hypnosis, therapeutic massage and healing touch with each cycle of chemotherapy. The control arm received chemotherapy without CM-IM. All patients completed QoL questionnaires prior to cycles 1, 3 and 6, and 6-months after chemotherapy. Immunologic profiles were measured. Statistical analysis was based on intent-to-treat. Student's t-test and Fischer's exact-test were used to determine differences. Results: Forty-three women enrolled. All women randomized to CM-IM were successfully treated. There were no statistical differences between the groups in age, stage, grade, histologic cell type, CA125 levels, or surgical cytoreductive status. There was no difference in overall QoL measurements. Re-hospitalization rates, treatment delays, anti-emetic use, and infection rates were similar. Immunologic profiles revealed no difference between arms for WBC or salivary IgA levels. Women receiving CM-IM had consistently higher levels of CD4, CD8 and NK cells, although this did not reach statistical significance. Conclusions: Prospective clinical evaluation of integrative medicine for women with gynecologic malignancy is feasible. This first, pilot study of CM-IM in gynecologic oncology demonstrated no improvement in QoL or chemotherapy toxicity. Integrative medicine-associated improvements in immunologic profiles warrant further investigation.

Original languageEnglish (US)
Pages (from-to)346-350
Number of pages5
JournalGynecologic Oncology
Volume123
Issue number2
DOIs
StatePublished - Nov 1 2011

Fingerprint

Integrative Medicine
Ovarian Neoplasms
Drug Therapy
Quality of Life
Antiemetics
Massage
Hypnosis
Touch
Natural Killer Cells
Immunoglobulin A
Neoplasms
Hospitalization
Therapeutics
Age Groups
Students

Keywords

  • Healing touch
  • Integrative medicine
  • Ovarian cancer
  • Prospective
  • Randomized
  • Therapeutic massage

Cite this

A prospective, randomized trial of integrative medicine for women with ovarian cancer. / Judson, Patricia L.; Dickson, Elizabeth L; Argenta, Peter A; Xiong, Yin; Geller, Melissa A; Carson, Linda F; Ghebre, Rahel G; Jonson, Amy L.; Downs, Levi S.

In: Gynecologic Oncology, Vol. 123, No. 2, 01.11.2011, p. 346-350.

Research output: Contribution to journalArticle

Judson, Patricia L. ; Dickson, Elizabeth L ; Argenta, Peter A ; Xiong, Yin ; Geller, Melissa A ; Carson, Linda F ; Ghebre, Rahel G ; Jonson, Amy L. ; Downs, Levi S. / A prospective, randomized trial of integrative medicine for women with ovarian cancer. In: Gynecologic Oncology. 2011 ; Vol. 123, No. 2. pp. 346-350.
@article{a4e1dea076904a2096b6b1d35ffd94e9,
title = "A prospective, randomized trial of integrative medicine for women with ovarian cancer",
abstract = "Objectives: Despite increased use of integrative medicine in cancer therapy, little data exist on its efficacy. This prospective, randomized, pilot trial sought to evaluate the feasibility of combined modality integrative medicine (CM-IM) in women with ovarian cancer (OvCA) and evaluate its effects on quality of life (QoL), chemotherapy toxicity and immunologic profiles. Methods: Women with newly diagnosed OvCA requiring chemotherapy were offered enrollment. Those randomized to the experimental arm received hypnosis, therapeutic massage and healing touch with each cycle of chemotherapy. The control arm received chemotherapy without CM-IM. All patients completed QoL questionnaires prior to cycles 1, 3 and 6, and 6-months after chemotherapy. Immunologic profiles were measured. Statistical analysis was based on intent-to-treat. Student's t-test and Fischer's exact-test were used to determine differences. Results: Forty-three women enrolled. All women randomized to CM-IM were successfully treated. There were no statistical differences between the groups in age, stage, grade, histologic cell type, CA125 levels, or surgical cytoreductive status. There was no difference in overall QoL measurements. Re-hospitalization rates, treatment delays, anti-emetic use, and infection rates were similar. Immunologic profiles revealed no difference between arms for WBC or salivary IgA levels. Women receiving CM-IM had consistently higher levels of CD4, CD8 and NK cells, although this did not reach statistical significance. Conclusions: Prospective clinical evaluation of integrative medicine for women with gynecologic malignancy is feasible. This first, pilot study of CM-IM in gynecologic oncology demonstrated no improvement in QoL or chemotherapy toxicity. Integrative medicine-associated improvements in immunologic profiles warrant further investigation.",
keywords = "Healing touch, Integrative medicine, Ovarian cancer, Prospective, Randomized, Therapeutic massage",
author = "Judson, {Patricia L.} and Dickson, {Elizabeth L} and Argenta, {Peter A} and Yin Xiong and Geller, {Melissa A} and Carson, {Linda F} and Ghebre, {Rahel G} and Jonson, {Amy L.} and Downs, {Levi S}",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2011.07.099",
language = "English (US)",
volume = "123",
pages = "346--350",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A prospective, randomized trial of integrative medicine for women with ovarian cancer

AU - Judson, Patricia L.

AU - Dickson, Elizabeth L

AU - Argenta, Peter A

AU - Xiong, Yin

AU - Geller, Melissa A

AU - Carson, Linda F

AU - Ghebre, Rahel G

AU - Jonson, Amy L.

AU - Downs, Levi S

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objectives: Despite increased use of integrative medicine in cancer therapy, little data exist on its efficacy. This prospective, randomized, pilot trial sought to evaluate the feasibility of combined modality integrative medicine (CM-IM) in women with ovarian cancer (OvCA) and evaluate its effects on quality of life (QoL), chemotherapy toxicity and immunologic profiles. Methods: Women with newly diagnosed OvCA requiring chemotherapy were offered enrollment. Those randomized to the experimental arm received hypnosis, therapeutic massage and healing touch with each cycle of chemotherapy. The control arm received chemotherapy without CM-IM. All patients completed QoL questionnaires prior to cycles 1, 3 and 6, and 6-months after chemotherapy. Immunologic profiles were measured. Statistical analysis was based on intent-to-treat. Student's t-test and Fischer's exact-test were used to determine differences. Results: Forty-three women enrolled. All women randomized to CM-IM were successfully treated. There were no statistical differences between the groups in age, stage, grade, histologic cell type, CA125 levels, or surgical cytoreductive status. There was no difference in overall QoL measurements. Re-hospitalization rates, treatment delays, anti-emetic use, and infection rates were similar. Immunologic profiles revealed no difference between arms for WBC or salivary IgA levels. Women receiving CM-IM had consistently higher levels of CD4, CD8 and NK cells, although this did not reach statistical significance. Conclusions: Prospective clinical evaluation of integrative medicine for women with gynecologic malignancy is feasible. This first, pilot study of CM-IM in gynecologic oncology demonstrated no improvement in QoL or chemotherapy toxicity. Integrative medicine-associated improvements in immunologic profiles warrant further investigation.

AB - Objectives: Despite increased use of integrative medicine in cancer therapy, little data exist on its efficacy. This prospective, randomized, pilot trial sought to evaluate the feasibility of combined modality integrative medicine (CM-IM) in women with ovarian cancer (OvCA) and evaluate its effects on quality of life (QoL), chemotherapy toxicity and immunologic profiles. Methods: Women with newly diagnosed OvCA requiring chemotherapy were offered enrollment. Those randomized to the experimental arm received hypnosis, therapeutic massage and healing touch with each cycle of chemotherapy. The control arm received chemotherapy without CM-IM. All patients completed QoL questionnaires prior to cycles 1, 3 and 6, and 6-months after chemotherapy. Immunologic profiles were measured. Statistical analysis was based on intent-to-treat. Student's t-test and Fischer's exact-test were used to determine differences. Results: Forty-three women enrolled. All women randomized to CM-IM were successfully treated. There were no statistical differences between the groups in age, stage, grade, histologic cell type, CA125 levels, or surgical cytoreductive status. There was no difference in overall QoL measurements. Re-hospitalization rates, treatment delays, anti-emetic use, and infection rates were similar. Immunologic profiles revealed no difference between arms for WBC or salivary IgA levels. Women receiving CM-IM had consistently higher levels of CD4, CD8 and NK cells, although this did not reach statistical significance. Conclusions: Prospective clinical evaluation of integrative medicine for women with gynecologic malignancy is feasible. This first, pilot study of CM-IM in gynecologic oncology demonstrated no improvement in QoL or chemotherapy toxicity. Integrative medicine-associated improvements in immunologic profiles warrant further investigation.

KW - Healing touch

KW - Integrative medicine

KW - Ovarian cancer

KW - Prospective

KW - Randomized

KW - Therapeutic massage

UR - http://www.scopus.com/inward/record.url?scp=80054770312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054770312&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.07.099

DO - 10.1016/j.ygyno.2011.07.099

M3 - Article

C2 - 21864886

AN - SCOPUS:80054770312

VL - 123

SP - 346

EP - 350

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -